Top Ten most popular articles on Pharmafile.com this week
pharmafile | September 1, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Cancer, Trump, drugs, health, life sciences, medicine, pharma, pharmaceutical, top ten
This week saw the news of a breakthrough in bispecific antibody production and Merck KGaA finally secured approval for its multiple sclerosis drug after seven years.
Also big news was the release of a government commissioned sector report authored by Sir John Bell, Professor of medicine at the University of Oxford, which sets out how life sciences can form a core part of the UK economy as the UK’s divorce from the EU nears.
But unsurprisingly, the most popular article this week was the news that Novartis received FDA approval for its “historic” CAR T treatment for acute lymphoblastic leukaemia in children.
Check out the week’s ten most popular articles on Pharmafile.com now!
10. New research reports first-ever response of central nervous tumour to CAR T therapy
Researchers at a General Hospital in Massachusetts has reported what they claim is the first response of a nervous system tumour to chimeric antigen receptor T-cell (CAR T) cancer therapy.
9. Seven years later, EC gives approval for Merck KGaA’s MS drug
The seven-year-long road to recovery for Mavenclad has finally been achieved, as it received the nod from the European Commission to treat patients with highly active relapsing multiple sclerosis.
8. Roche receives FDA Priority Review for drug with potted history
Roche, alongside its subsidiary, Genentech, announced that it has received Priority Review for its haemophilia A drug, emicizumab, and that the agency has accepted its BLA.
7. Immunotherapy firm develops breakthrough method for robust bispecific antibody production
A team of researchers have developed an approach to efficiently manufacture bispecific antibodies which are able to bind to two separate target molecules simultaneously.
6. FDA approves first treatment for the ‘silent killer’
The FDA has announced that it has granted an accelerated approval for the use of benznidazole in children between the ages of 2 and 12 years old with Chagas disease.
5. AstraZeneca invests “tens of millions” into Cheshire, UK manufacturing site
AstraZeneca has announced plans to invest a multi-million sum into its £150 million facility in Macclesfield, Chesire, UK – a move which the company said is “part of our ongoing investment in the UK”.
4. The pharmacovigilance market dynamic
Pharmacovigilance is a science of understanding drug safety through identification, assessment, and prevention of adverse drug reactions.
3. Has Trump’s power over pharma come to an end after Charlottesville?
Pivotal moment for the relationship between Donald Trump and industry, as MSD CEO Kenneth Frazier leads the collapse of the President’s manufacturing committee.
2. UK’s post-Brexit strategy looks to life sciences industry
A new report has been published looking at how the life sciences can form a core part of the UK’s industrial growth.
1. CAR-T treatment is given ‘historic’ first approval by FDA
Novartis has received approval for its CAR-T treatment of paediatric and young adults with a form of acute lymphoblastic leukaemia (ALL).
Related Content
Amphista doses first patient in AML trial of protein degrader
Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …
Digital platform cuts pharmaceutical quality-record approval times by up to 90%
A digital platform for exchanging pharmaceutical quality records between supply-chain partners is now commercially available, …
Agentic commercial: how AI creates dialogue with HCPs and patients to help medicines reach them faster
By Chris Moore Commercial engagement in biopharma used to centre largely on direct conversations between …
